Fluoropharma is engaged in the discovery, development and commercialization of molecular imaging pharmaceuticals with primary applications in the area of cardiology. The company’s BFPET is in phase I trial used for the detection of ischemic and infarcted tissue within the myocardium in patients with suspected or proven chronic CAD. CardioPET is in phase II development stage for the assessment of myocardial metabolism. For further information, visit the company’s Web site at: www.fluoropharma.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: